COGT
Cogent Biosciences, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
36.33
▲ 1.02 (2.88%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
35.45
Prev close
35.31
Day high
37.22
Day low
35.40
Volume
2.36M
Market cap
—
P/E (TTM)
—
52W range
11.60 – 43.73
Trailing performance
Returnvs SPY
1W
-3.16%
-1.8%
1M
-8.72%
-12.5%
3M
+12.74%
+9.6%
6M
-1.63%
-12.7%
YTD
+3.41%
-8.9%
1Y
+209.57%
+189.6%
3Y
+211.54%
+137.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on COGT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $269.78M | $232.66M | $173.75M | $121.63M | +16.0% |
| Selling, general & admin | $63.58M | $43.28M | $34.38M | $26.21M | +46.9% |
| Total operating expense | $333.36M | $275.94M | $208.13M | $147.84M | +20.8% |
| Operating income | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -20.8% |
| Net interest income | $11.63M | $18.09M | $13.08M | $3.99M | -35.7% |
| Pre-tax income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Net income to common | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Basic EPS | -2.04 | -2.32 | -2.42 | -2.39 | +11.8% |
| Diluted EPS | -2.04 | -2.32 | -2.42 | -2.39 | +11.8% |
| EBIT | -$325.88M | -$255.86M | -$192.41M | -$147.84M | -27.4% |
| EBITDA | -$321.29M | -$251.51M | -$188.82M | -$141.96M | -27.7% |
| Basic shares | 160.98M | 110.46M | 79.66M | 58.74M | +45.7% |
| Diluted shares | 160.98M | 110.46M | 79.66M | 58.74M | +45.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $312.01M | $98.17M | $53.23M | $139.89M | +217.8% |
| Cash & short-term investments | $900.76M | $287.08M | $265.71M | $259.28M | +213.8% |
| Total current assets | $910.36M | $296.47M | $270.77M | $264.97M | +207.1% |
| Property, plant & equipment | $23.54M | $26.56M | $30.34M | $31.10M | -11.4% |
| Total assets | $937.61M | $327.90M | $313.44M | $300.81M | +185.9% |
| Total current liabilities | $63.95M | $55.71M | $38.17M | $26.85M | +14.8% |
| Long-term debt | $222.90M | — | — | — | — |
| Total debt | $238.80M | $17.47M | $18.85M | $19.65M | +1,267.1% |
| Total liabilities | $301.24M | $71.61M | $55.63M | $45.08M | +320.7% |
| Retained earnings | -$1.19B | -$859.48M | -$603.62M | -$411.21M | -38.3% |
| Shareholder equity | $636.37M | $256.29M | $257.80M | $255.74M | +148.3% |
| Working capital | $846.40M | $240.76M | $232.60M | $238.12M | +251.6% |
| Net tangible assets | $636.37M | $256.29M | $257.80M | $255.74M | +148.3% |
| Shares issued | 160.98M | 110.46M | 86.12M | 69.89M | +45.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -28.6% |
| Depreciation & amortisation | $4.58M | $4.35M | $3.59M | $5.88M | +5.3% |
| Stock-based compensation | $46.08M | $39.74M | $30.62M | $18.37M | +16.0% |
| Change in working capital | $8.01M | $11.60M | $11.44M | $751.00K | -30.9% |
| Operating cash flow | -$264.44M | -$207.79M | -$153.62M | -$118.64M | -27.3% |
| Capital expenditure | -$1.55M | -$573.00K | -$2.80M | -$6.86M | -171.2% |
| Investing cash flow | -$399.53M | $38.28M | -$97.82M | -$124.72M | -1,143.8% |
| Financing cash flow | $878.23M | $214.45M | $163.54M | $163.56M | +309.5% |
| Free cash flow | -$266.00M | -$208.36M | -$156.42M | -$125.50M | -27.7% |
| End cash position | $312.43M | $98.17M | $53.23M | $141.14M | +218.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $75.36M | $75.56M | $68.99M | $62.20M | $63.03M | -0.3% |
| Selling, general & admin | $28.24M | $23.93M | $14.37M | $13.38M | $11.90M | +18.0% |
| Total operating expense | $103.61M | $99.49M | $83.36M | $75.58M | $74.93M | +4.1% |
| Operating income | -$103.61M | -$99.49M | -$83.36M | -$75.58M | -$74.93M | -4.1% |
| Net interest income | $6.39M | $4.19M | $2.43M | $2.06M | $2.95M | +52.7% |
| Pre-tax income | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | +5.0% |
| Net income | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | +5.0% |
| Net income to common | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | +5.0% |
| Basic EPS | -0.57 | -0.64 | -0.58 | -0.65 | -0.63 | +10.5% |
| Diluted EPS | -0.57 | -0.64 | -0.58 | -0.65 | -0.63 | +10.5% |
| EBIT | -$96.14M | -$101.20M | -$79.47M | -$73.22M | -$71.99M | +5.0% |
| EBITDA | -$94.98M | -$100.06M | -$78.32M | -$72.06M | -$70.85M | +5.1% |
| Basic shares | 170.77M | 160.98M | 139.83M | 113.93M | 113.86M | +6.1% |
| Diluted shares | 170.77M | 160.98M | 139.83M | 113.93M | 113.86M | +6.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $241.21M | $312.01M | $125.30M | $127.60M | $126.00M | -22.7% |
| Cash & short-term investments | $866.38M | $900.76M | $390.89M | $237.85M | $245.66M | -3.8% |
| Total current assets | $877.80M | $910.36M | $397.24M | $245.01M | $252.88M | -3.6% |
| Property, plant & equipment | $22.85M | $23.54M | $23.86M | $24.95M | $26.05M | -2.9% |
| Total assets | $903.01M | $937.61M | $425.93M | $274.82M | $283.80M | -3.7% |
| Total current liabilities | $57.98M | $63.95M | $62.25M | $58.42M | $49.32M | -9.3% |
| Long-term debt | $223.17M | $222.90M | $44.25M | $43.95M | — | +0.1% |
| Total debt | $238.65M | $238.80M | $60.56M | $60.66M | $17.09M | -0.1% |
| Total liabilities | $295.31M | $301.24M | $123.47M | $119.78M | $64.80M | -2.0% |
| Retained earnings | -$1.29B | -$1.19B | -$1.09B | -$1.00B | -$931.47M | -8.2% |
| Shareholder equity | $607.69M | $636.37M | $302.46M | $155.04M | $219.00M | -4.5% |
| Working capital | $819.82M | $846.40M | $335.00M | $186.59M | $203.57M | -3.1% |
| Net tangible assets | $607.69M | $636.37M | $302.46M | $155.04M | $219.00M | -4.5% |
| Shares issued | 170.77M | 160.98M | 139.83M | 113.93M | 113.86M | +6.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | +5.0% |
| Depreciation & amortisation | $1.16M | $1.14M | $1.15M | $1.16M | $1.14M | +1.2% |
| Stock-based compensation | $16.91M | $15.75M | $10.60M | $9.72M | $10.01M | +7.3% |
| Change in working capital | -$6.83M | $132.00K | $4.76M | $7.83M | -$4.72M | -5,272.0% |
| Operating cash flow | -$86.88M | -$79.11M | -$64.29M | -$54.54M | -$66.51M | -9.8% |
| Capital expenditure | -$449.00K | -$811.00K | -$65.00K | -$131.00K | -$547.00K | +44.6% |
| Investing cash flow | -$36.46M | -$322.77M | -$155.05M | $8.91M | $69.38M | +88.7% |
| Financing cash flow | $52.54M | $588.67M | $217.37M | $47.23M | $24.97M | -91.1% |
| Free cash flow | -$87.33M | -$79.92M | -$64.35M | -$54.67M | -$67.06M | -9.3% |
| End cash position | $241.62M | $312.43M | $125.63M | $127.60M | $126.00M | -22.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.86
-4.05% from price
SMA 20
39.39
-6.75% from price
SMA 50
38.34
-4.19% from price
SMA 100
36.61
-0.78% from price
SMA 200
36.48
+0.68% from price
EMA 12
37.96
-4.29% from price
EMA 26
38.57
-5.81% from price
EMA 50
38.14
-4.76% from price
RSI (14)
42.9
Neutral
MACD (12,26,9)
-0.61
Hist -0.59
ATR (14)
1.93
5.25% of price
Realised vol 30D
54.0%
Annualised
Bollinger upper
43.64
20, 2σ
Bollinger lower
35.14
20, 2σ
50 / 200 cross
Golden
38.34 vs 36.48
Trend bias
Above 200
+0.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.44
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
54.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-26.3%
Peak to trough
Max drawdown 5Y
-76.3%
Peak to trough
ATR 14
1.93
5.25% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Biotech ETF (CANC) Hits New 52-Week High
Zacks · 3d ago
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks · 10d ago
Cogent Biosciences Q2 Loss Widens
MT Newswires · 13d ago
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib
Insider Monkey · 39d ago
MEDevice Boston 2026: East Coast's Top Medical Device Conference Opens Registration for August 26-27 Event
GlobeNewswire · 48d ago
Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment
MT Newswires · 54d ago
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
GlobeNewswire · 54d ago
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
Insider Monkey · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.